Pure Global
NCT06316284

miRNA in Chronic Kidney Diseases

The Role of miRNAs in the Regulation of Oxidative Stress and Microvascular Reactivity in Chronic Kidney Disease
Josip Juraj Strossmayer University of Osijek·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chronic Kidney Diseases
Study type
Observational
Sponsor & location
Primary sponsor
Josip Juraj Strossmayer University of Osijek
Location
Osijek, Croatia
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2024
End date
Dec 31, 2026
Enrollment
90 participants
Primary outcome

Systemic microvascular function,Serum level of antixidant enzymesprotein concentration of SOD, CAT and glutathione-peroxidase,Detecton of miRNA of interest

Summary

Oxidative stress and endoplasmic reticulum (ER) stress play a key role in tubular damage in
 both acute kidney injury and chronic kidney disease (CKD). Oxidative stress in the kidneys
 promotes renal vascular remodeling and increases preglomerular resistance. These are key
 elements in hypertension, acute and chronic kidney injury, as well as diabetic nephropathy.
 Chronic renal hypoxia is highlighted as the final common pathway to end-stage renal disease
 (ESRD). MicroRNA molecules (miRNA) also play an important role in these processes. MicroRNAs
 (miRNAs) are regulators of gene expression and play a role in the progression of renal
 ischemia-reperfusion injury. Although the pathophysiological contribution of microRNAs
 (miRNAs) to kidney damage has also been highlighted, the effect of miRNAs on kidney damage
 under conditions of oxidative and ER stress remains understudied.

ICD-10 classifications
Chronic kidney diseaseChronic kidney disease, unspecifiedChronic kidney disease, stage 1Chronic kidney disease, stage 4Chronic kidney disease, stage 2
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06316284
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06316284 through Pure Global AI's free database. This phase not specified trial is sponsored by Josip Juraj Strossmayer University of Osijek and is currently Not yet recruiting. The study focuses on Chronic Kidney Diseases. Target enrollment is 90 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.